After surprise FDA win, Aveo reverts to normal as partner splits, giving back unwanted asset

After getting an FDA approval for its long-suffering cancer med from the FDA this month, Aveo’s brief positive news was upset by reverting to type after partner CANbridge said thanks but no thanks to an experimental drug.